Business / Finance RSS Feed - Business / Finance

Abaxis completes acquisition of QCR & Trio Diagnostics

Abaxis completes acquisition of QCR & Trio Diagnostics

Abaxis, Inc., a medical products company manufacturing point-of-care instruments and consumables for the medical, research, and veterinary markets worldwide and providing reference lab services to the veterinary and research markets in the United States, announced today the completion of a stock purchase agreement to acquire 100% of QCR & Trio Diagnostics Limited, a United Kingdom based distribution organization. [More]
Lexicon prices $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes

Lexicon prices $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes

Lexicon Pharmaceuticals, Inc. today announced that it has priced its offering of $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the "Convertible Notes") in a private offering within the United States. [More]
Lexicon announces pricing of underwritten public offering of common stock

Lexicon announces pricing of underwritten public offering of common stock

Lexicon Pharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering of $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement. [More]
Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") is pleased to announce that it has closed a brokered private placement offering (the "Brokered Offering") of special warrants for approximately C$3.7 million. [More]
Coqui Pharma signs contract with INVAP to design Medical Isotope Production Facility in Alachua, Fla

Coqui Pharma signs contract with INVAP to design Medical Isotope Production Facility in Alachua, Fla

Coqui RadioPharmaceuticals Corp., a medical isotope company working to become the first U.S. commercial producer of Molybdenum-99 (Mo-99), is proud to announce it has formally signed a contract with INVAP to design its Medical Isotope Production Facility (MIPF) in Alachua, Fla. Mo-99 is the parent isotope of Technetium-99, which is used in 80 percent of nuclear medicine procedures worldwide. [More]
Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals. [More]
Cyberonics' worldwide net sales increase 5% to $73.4M in Q2 of fiscal 2015

Cyberonics' worldwide net sales increase 5% to $73.4M in Q2 of fiscal 2015

Cyberonics, Inc. today announced results for the quarter ended October 24, 2014. [More]
Echo Therapeutics reports net loss of $5.5 million for third quarter 2014

Echo Therapeutics reports net loss of $5.5 million for third quarter 2014

Echo Therapeutics, Inc., a medical device company, today announced its financial results for the quarter ended September 30, 2014. [More]
EvergreenHealth, Valley General Hospital approve final phase of alliance agreement

EvergreenHealth, Valley General Hospital approve final phase of alliance agreement

EvergreenHealth and Valley General Hospital announced today that their respective Boards of Commissioners have voted to approve the third and final phase of an alliance agreement in which Valley General Hospital in Monroe, Washington will become part of the Kirkland-based health care system and managed by EvergreenHealth. [More]
Moffitt announces development of innovative investigational biologic agent for MDS

Moffitt announces development of innovative investigational biologic agent for MDS

In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
EKF Diagnostics and Joslin Diabetes Center enter collaborative relationship

EKF Diagnostics and Joslin Diabetes Center enter collaborative relationship

EKF Diagnostics, the global diagnostics company, has entered a multi-year, collaborative relationship with Joslin Diabetes Center (“Joslin”) in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers. These novel biomarkers can help identify patients with Type 1 and Type 2 diabetes that are at an increased risk of developing end stage renal disease (ESRD), up to ten years in advance. [More]

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014. [More]
Escalon Medical reports net loss of $458,959 for first quarter of fiscal 2015

Escalon Medical reports net loss of $458,959 for first quarter of fiscal 2015

Escalon Medical Corp. today announced its operating results for its fiscal 2015 first quarter ended September 30, 2014. [More]
Biosafe gears up its activities in China with major expansion of Shanghai-based operations

Biosafe gears up its activities in China with major expansion of Shanghai-based operations

Following the full registration of its product range by the Chinese FDA last April, Biosafe is gearing up its activities in the People's Republic of China with a major expansion of its Shanghai-based operations, including staffing and facilities consolidation. [More]
CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, today reported financial results for the three and nine months ended September 30, 2014. [More]
PDL BioPharma receives $30.3M to conclude revenue interest contract with AxoGen

PDL BioPharma receives $30.3M to conclude revenue interest contract with AxoGen

PDL BioPharma, Inc. (PDL) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc. [More]

China Pharma’s revenues decrease $5.5M to 31% in third quarter 2014

China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma" or the "Company"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended September 30, 2014. [More]
Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. [More]
Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014. [More]